These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35327341)

  • 21. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.
    Zettl UK; Rommer P; Hipp P; Patejdl R
    Ther Adv Neurol Disord; 2016 Jan; 9(1):9-30. PubMed ID: 26788128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison.
    Dal Canto MC; Melvold RW; Kim BS; Miller SD
    Microsc Res Tech; 1995 Oct; 32(3):215-29. PubMed ID: 8527856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.
    Pryce G; Riddall DR; Selwood DL; Giovannoni G; Baker D
    J Neuroimmune Pharmacol; 2015 Jun; 10(2):281-92. PubMed ID: 25537576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theiler's virus-induced demyelinating disease as an infectious model of progressive multiple sclerosis.
    Pike SC; Welsh N; Linzey M; Gilli F
    Front Mol Neurosci; 2022; 15():1019799. PubMed ID: 36311024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX
    Turri M; Teatini F; Donato F; Zanette G; Tugnoli V; Deotto L; Bonetti B; Squintani G
    Medicines (Basel); 2018 Jun; 5(3):. PubMed ID: 29933552
    [No Abstract]   [Full Text] [Related]  

  • 30. Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.
    Flachenecker P; Saccà F; Vila C
    Case Rep Neurol; 2018; 10(2):169-176. PubMed ID: 30140216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.
    Elliott DM; Singh N; Nagarkatti M; Nagarkatti PS
    Front Immunol; 2018; 9():1782. PubMed ID: 30123217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.
    Akgün K; Essner U; Seydel C; Ziemssen T
    J Cent Nerv Syst Dis; 2019; 11():1179573519831997. PubMed ID: 30886530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus.
    Mecha M; Carrillo-Salinas FJ; Mestre L; Feliú A; Guaza C
    Prog Neurobiol; 2013; 101-102():46-64. PubMed ID: 23201558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.
    Feliú A; Bonilla Del Río I; Carrillo-Salinas FJ; Hernández-Torres G; Mestre L; Puente N; Ortega-Gutiérrez S; López-Rodríguez ML; Grandes P; Mecha M; Guaza C
    J Neurosci; 2017 Aug; 37(35):8385-8398. PubMed ID: 28751457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V; Centonze D
    CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.